Journal
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
Volume 37, Issue 1, Pages 876-894Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/14756366.2022.2050224
Keywords
Anidulafungin; caspofungin; micafungin; rezafungin; drug resistance; chemical modification
Funding
- Ministry of Education and Science, Poland
- Faculty of Chemistry of the University of Bialystok
Ask authors/readers for more resources
Echinocandins inhibit fungal cell wall synthesis by targeting beta-(1,3)-D-glucan, offering potential for novel derivatives with improved pharmacological properties. These drugs show promise in more effectively treating infections caused by Candida and Aspergillus species.
With increasing number of immunocompromised patients as well as drug resistance in fungi, the risk of fatal fungal infections in humans increases as well. The action of echinocandins is based on the inhibition of beta-(1,3)-d-glucan synthesis that builds the fungal cell wall. Caspofungin, micafungin, anidulafungin and rezafungin are semi-synthetic cyclic lipopeptides. Their specific chemical structure possess a potential to obtain novel derivatives with better pharmacological properties resulting in more effective treatment, especially in infections caused by Candida and Aspergillus species. In this review we summarise information about echinocandins with closer look on their chemical structure, mechanism of action, drug resistance and usage in clinical practice. We also introduce actual trends in modification of this antifungals as well as new methods of their administration, and additional use in viral and bacterial infections.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available